Award
NIH Reporter #5UH3HL148693-04
A Study Evaluating the Safety and Efficacy of Second-Generation Tissue Engineered Vascular Grafts (TEVG2)
Recipient
Research Institute Nationwide Children's Hospital
Award Amount
$593,214.00
Ceiling
$593,214.00
Awarded
February 12, 2024
Identifier
5UH3HL148693-04
NIH awarded $593,214 to Research Institute Nationwide Children's Hospital for a study evaluating the safety and efficacy of second-generation tissue engineered vascular grafts in pediatric patients with congenital heart defects.
Description
This project involves the development and clinical evaluation of second-generation tissue engineered vascular grafts (TEVG2) designed for use in children with congenital heart defects. The study aims to assess the safety and efficacy of the TEVG2 over a 2-year period in 24 pediatric patients undergoing modified Fontan surgery. The TEVG is made by seeding autologous bone marrow-derived mononuclear cells onto a biodegradable scaffold, which transforms into a neovessel resembling a native blood vessel.